HighTower Advisors’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.72M Sell
21,025
-13,719
-39% -$3.42M 0.01% 1225
2025
Q4
$8.37M Buy
34,744
+1,377
+4% +$352K 0.01% 933
2025
Q3
$9.15M Sell
33,367
-3,638
-10% -$994K 0.01% 885
2025
Q2
$9.55M Sell
37,005
-2,669
-7% -$637K 0.01% 819
2025
Q1
$8.88M Buy
39,674
+6,764
+21% +$1.58M 0.01% 812
2024
Q4
$7.53M Buy
32,910
+3,690
+13% +$888K 0.01% 875
2024
Q3
$7.1M Buy
29,220
+1,708
+6% +$382K 0.01% 891
2024
Q2
$5.27M Buy
27,512
+3,124
+13% +$634K 0.01% 985
2024
Q1
$4.84M Buy
24,388
+287
+1% +$52.6K 0.01% 981
2023
Q4
$4.14M Sell
24,101
-24,821
-51% -$3.81M 0.01% 1070
2023
Q3
$7.21M Buy
48,922
+4,959
+11% +$897K 0.01% 772
2023
Q2
$9.61M Sell
43,963
-507
-1% -$113K 0.02% 663
2023
Q1
$9.76M Buy
44,470
+1,540
+4% +$334K 0.02% 635
2022
Q4
$8.9M Sell
42,930
-268
-0.6% -$58.9K 0.02% 652
2022
Q3
$9.41M Sell
43,198
-10,560
-20% -$2.4M 0.03% 583
2022
Q2
$11.3M Sell
53,758
-18,380
-25% -$3.91M 0.03% 533
2022
Q1
$17.5M Sell
72,138
-4,277
-6% -$1.03M 0.04% 424
2021
Q4
$19.9M Buy
76,415
+25,531
+50% +$6.62M 0.04% 381
2021
Q3
$13.4M Buy
50,884
+299
+0.6% +$81.8K 0.04% 431
2021
Q2
$12.4M Buy
50,585
+1,934
+4% +$407K 0.04% 446
2021
Q1
$9.51M Buy
48,651
+1,821
+4% +$365K 0.03% 500
2020
Q4
$9.89M Buy
46,830
+12,314
+36% +$2.46M 0.04% 376
2020
Q3
$5.9M Buy
34,516
+9,139
+36% +$1.69M 0.03% 494
2020
Q2
$4.88M Sell
25,377
-1,502
-6% -$246K 0.03% 521
2020
Q1
$3.95M Sell
26,879
-32,587
-55% -$5.19M 0.03% 522
2019
Q4
$9.2M Buy
59,466
+7,482
+14% +$1.08M 0.05% 359
2019
Q3
$7.01M Buy
51,984
+2,106
+4% +$276K 0.04% 441
2019
Q2
$6.1M Sell
49,878
-9
-0% -$997 0.04% 489
2019
Q1
$5.13M Sell
49,887
-14,478
-22% -$1.49M 0.03% 492
2018
Q4
$7.33M Sell
64,365
-627
-1% -$67.2K 0.06% 349
2018
Q3
$7.5M Sell
64,992
-3,317
-5% -$363K 0.05% 377
2018
Q2
$7.02M Sell
68,309
-401
-0.6% -$40.6K 0.06% 385
2018
Q1
$6.81M Sell
68,710
-191
-0.3% -$18K 0.06% 369
2017
Q4
$5.83M Sell
68,901
-1,506
-2% -$124K 0.05% 422
2017
Q3
$5.4M Buy
70,407
+1,084
+2% +$82.9K 0.05% 438
2017
Q2
$5.38M Sell
69,323
-497
-0.7% -$35.6K 0.05% 435
2017
Q1
$5.01M Buy
69,820
+10,215
+17% +$706K 0.05% 431
2016
Q4
$3.69M Buy
59,605
+2,007
+3% +$123K 0.04% 495
2016
Q3
$3.73M Buy
57,598
+468
+0.8% +$31.2K 0.04% 454
2016
Q2
$3.61M Sell
57,130
-4,728
-8% -$279K 0.05% 431
2016
Q1
$3.57M Buy
+61,858
New +$3.5M 0.01% 496
2015
Q4
Sell
-51,790
Closed -$2.69M 2127
2015
Q3
$2.69M Buy
51,790
+1,963
+4% +$106K 0.04% 502
2015
Q2
$2.81M Buy
+49,827
New +$3.14M 0.05% 438
2015
Q1
Sell
-46,389
Closed -$2.6M 1684
2014
Q4
$2.6M Buy
46,389
+9,389
+25% +$490K 0.04% 491
2014
Q3
$1.82M Buy
37,000
+1,332
+4% +$67.8K 0.03% 587
2014
Q2
$1.81M Buy
35,668
+20,587
+137% +$1.02M 0.03% 591
2014
Q1
$696K Buy
+15,081
New +$677K 0.01% 865

Other funds holding RMD

HighTower Advisors's RMD Position: Q1 2026 in Review

HighTower Advisors reduced its ResMed (RMD) stake by 39% in Q1 2026, selling an estimated $3.42M and leaving 21,025 shares worth $4.72M. The position accounts for 0.01% of the portfolio, ranked #1225.

HighTower Advisors first reported a position in RMD in Q1 2014 and has held it in 47 quarters since. The position peaked at $19.9M in Q4 2021. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • HighTower Advisors held 21,025 shares of ResMed worth $4.72M as of Q1 2026.
  • HighTower Advisors sold 13,719 ResMed shares in Q1 2026, an estimated $3.42M.
  • ResMed made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #1225 holding.
  • HighTower Advisors first reported a position in ResMed in Q1 2014 and has held it in 47 quarters since.
  • HighTower Advisors's ResMed position peaked at $19.9M in Q4 2021.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.